Nls Pharmaceutics Ag Stock Earnings Per Share
| NLSPW Stock | USD 0.01 0 11.11% |
NLS Pharmaceutics AG fundamentals help investors to digest information that contributes to NLS Pharmaceutics' financial success or failures. It also enables traders to predict the movement of NLS Stock. The fundamental analysis module provides a way to measure NLS Pharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NLS Pharmaceutics stock.
NLS | Earnings Per Share |
NLS Pharmaceutics AG Company Earnings Per Share Analysis
NLS Pharmaceutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
NLS Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for NLS Pharmaceutics is extremely important. It helps to project a fair market value of NLS Stock properly, considering its historical fundamentals such as Earnings Per Share. Since NLS Pharmaceutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NLS Pharmaceutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NLS Pharmaceutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
NLS Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, NLS Pharmaceutics AG has an Earnings Per Share of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
NLS Pharmaceutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of NLS Pharmaceutics from analyzing NLS Pharmaceutics' financial statements. These drivers represent accounts that assess NLS Pharmaceutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NLS Pharmaceutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 557.1M | 654.8M | 1.0B | 897.9M | 1.1B | |
| Enterprise Value | 1.3B | 559.1M | 649.4M | 1.0B | 898.6M | 1.1B |
NLS Fundamentals
| Return On Asset | -2.28 | ||||
| Number Of Shares Shorted | 24.07 K | ||||
| EBITDA | (11.8 M) | ||||
| Net Income | (12.17 M) | ||||
| Cash And Equivalents | 145.4 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 1.63 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (9.40) X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Beta | -0.52 | ||||
| Market Capitalization | 37.77 M | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (70.37 M) | ||||
| Working Capital | (6.1 M) | ||||
| Net Asset | 1.85 M |
About NLS Pharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NLS Pharmaceutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NLS Pharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NLS Pharmaceutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.